Cancer News and Research

Latest Cancer News and Research

N.J. Gov. still undecided on whether to join lawsuit against overhaul while health care costs roil Mass. Governor's race

The Philadelphia Inquirer: N.J. "Gov. Christie says he has not decided whether to sign on to a 20-state lawsuit challenging the constitutionality of the health-care law signed in March by President Obama. That makes New Jersey one of seven Republican-led states that have not joined the largely partisan fight. Interest groups on both sides of the debate are lobbying the governor, but some of his advisers say he should not join the suit.

29 Jun 2010

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Vietnam War-era veterans exposed to Agent Orange appear to have significantly more Graves' disease, a thyroid disorder, than veterans with no exposure, a new study by endocrinologists at the University at Buffalo has shown.

29 Jun 2010

Lead researchers develop a novel technique to deliver cancer drugs

A new way to deliver cancer drugs using gas bubbles and sound waves is to be developed at the University of Leeds. The project will enable highly toxic drugs to be delivered in small doses directly to tumours, where their toxicity can safely be put to good use.

29 Jun 2010

Cell>Point completes cancer diagnostic phase 2 trial; reports favorable trends in primary tumor imaging

Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer.

29 Jun 2010

SurgiVision's ClearPoint system granted 510(k) clearance for neurological interventional procedures

DARA BioSciences, Inc., announced today that SurgiVision, Inc., a privately held company of which DARA owns 1,613,258 shares and warrants to purchase an additional 405,000 shares, has received 510(k) clearance from the Food and Drug Administration (FDA) to market their ClearPoint system in the United States for general neurological interventional procedures.

29 Jun 2010

'Beeglue' may help deliver new treatments for fatal infections

Bees could have a key role to play in urgently-needed new treatments to fight the virulent MRSA bug, according to research led at the University of Strathclyde in Glasgow, Scotland.

29 Jun 2010

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

The Associated Press: "Americans increasingly are treated to death, spending more time in hospitals in their final days, trying last-ditch treatments that often buy only weeks of time, and racking up bills that have made medical care a leading cause of bankruptcies. More than 80 percent of people who die in the United States have a long, progressive illness such as cancer, heart failure or Alzheimer's disease."

29 Jun 2010

Cancer clues from pregnant lizards

A compound produced by a pregnant lizard may provide important information on the origins and treatment of cancer in humans, according to zoologist Bridget Murphy from the School of Biological Sciences who discovered the protein, which is pivotal to the development of the lizard placenta.

28 Jun 2010

Getting rid of asbestos in Australia

Asbestos that is linked to lung cancer called mesothelioma, is still present in more than one million Australian homes, offices and schools according to reports. And the problem is “compounded by poor community awareness and a disjointed approach from the three levels of government.”

28 Jun 2010

People in Medicare's two-year disability waiting period continue to wait

The Oregonian: Sue Sherman of Southwest Portland was diagnosed with pancreatic cancer last year and "joined nearly 2 million disabled Americans -- at least 15,000 in Oregon -- who fall into a twilight with the first monthly Social Security disability payment, for they then must wait two years to become eligible for Medicare." Many of them exhaust their savings "on the care necessary to reach a diagnosis and now cannot get private insurance."

28 Jun 2010

Health reform law this week: Some states to miss deadline on high-risk pools, tanning tax kicks in

USA Today: "The key early program of the nation's new health law aims to provide affordable coverage to about 200,000 people with pre-existing medical conditions, such as cancer or diabetes, through federal high-risk insurance pools. The law called for the program to be in place last week, 90 days after its enactment, though the Department of Health and Human Services had said the programs would launch Thursday to coincide with the start of states' fiscal years."

28 Jun 2010

MagForce's Nano-Cancer therapy receives European regulatory approval

Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy.

28 Jun 2010

Rexahn announces $10 million registered direct offering

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced it has received commitments from certain institutional investors to purchase an aggregate of $10 million of Rexahn's securities in a registered direct offering.

28 Jun 2010

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Zeria Pharmaceutical announced today positive results of their Japanese Phase III study of Z-338 (acotiamide hydrochloride hydrate; "acotiamide") for the treatment of functional dyspepsia (FD). FD is a gastrointestinal disease comprised of subjective symptoms including postprandial fullness, early satiation and epigastric pain without any organic abnormality on gastrointestinal tract.

28 Jun 2010

Emerald, FORMA sign strategic partnership for structure-based design of cancer drug candidates

Emerald BioStructures, a leading provider of integrated structural biology services, and FORMA Therapeutics, a drug discovery company, today announced the signing of a strategic partnership for the structure-based design of cancer drug candidates for FORMA's pipeline.

28 Jun 2010

Fate Therapeutics recognized with Red Herring's North America 100 award

Fate Therapeutics, Inc. announced today that the Company received Red Herring's North America 100 award, a prestigious list honoring the year's most promising private and innovative companies from the North American business region. The nominees were evaluated by the Red Herring editorial team on both quantitative and qualitative criteria, such as financial performance, technology innovation, quality of management, execution of strategy and integration into their respective industries.

28 Jun 2010

BioSante joins Russell 3000 Index

BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.

28 Jun 2010

Masimo granted FDA clearance for Pronto-7 noninvasive hemoglobin spot-check testing device

Masimo, the inventor of Masimo Rainbow Pulse CO-Oximetry™, Masimo Rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, today announced FDA 510(k) clearance for the Pronto-7™—a new handheld device designed for quick and easy noninvasive hemoglobin (SpHb®) spot-check testing, along with SpO2, pulse rate, and perfusion index, in virtually any environment.

28 Jun 2010

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.

28 Jun 2010

Cancer News and Research

Latest Cancer News and Research

N.J. Gov. still undecided on whether to join lawsuit against overhaul while health care costs roil Mass. Governor's race

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Lead researchers develop a novel technique to deliver cancer drugs

Cell>Point completes cancer diagnostic phase 2 trial; reports favorable trends in primary tumor imaging

SurgiVision's ClearPoint system granted 510(k) clearance for neurological interventional procedures

'Beeglue' may help deliver new treatments for fatal infections

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

Cancer clues from pregnant lizards

Getting rid of asbestos in Australia

People in Medicare's two-year disability waiting period continue to wait

Health reform law this week: Some states to miss deadline on high-risk pools, tanning tax kicks in

MagForce's Nano-Cancer therapy receives European regulatory approval

Rexahn announces $10 million registered direct offering

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Emerald, FORMA sign strategic partnership for structure-based design of cancer drug candidates

Fate Therapeutics recognized with Red Herring's North America 100 award

BioSante joins Russell 3000 Index

Masimo granted FDA clearance for Pronto-7 noninvasive hemoglobin spot-check testing device

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

Cancer Research - Second Edition eBook

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in